This fixed research blend combines CJC-1295 No DAC and Ipamorelin at labelled 5 mg amounts. It is maintained independently from each single peptide and from other CJC variants.
No payment is taken online. Sales confirms availability, documentation, shipping, and commercial terms.
COA files are available in the document library; additional batch-specific documentation can be requested with your inquiry. Each batch is tested with HPLC purity analysis (≥98%). For MSDS or detailed storage protocols, please contact our sales team.
The combination of CJC-1295 NO DAC (Mod GRF 1-29) and Ipamorelin (IPA) represents a well-established synergistic regimen among growth hormone secretagogues. This dual-targeted approach aims to stimulate endogenous growth hormone (GH) pulsatile release through complementary pathways, achieving more pronounced anabolic effects than either compound alone.
Users commonly report enhanced muscle strength and endurance, reduced body fat (particularly visceral fat), improved sleep quality, enhanced skin elasticity, and accelerated recovery following surgery or training. A notable advantage of this combination is its ability to generate a "physiological" GH pulse pattern while exerting minimal impact on stress hormones including prolactin and cortisol, making it a relatively mild and sustainable pro-anabolic strategy, particularly suitable for individuals seeking body composition improvement, anti-aging benefits, and tissue repair support.
These two agents act on distinct nodes of pituitary growth hormone secretion regulation, producing a synergistic effect. CJC-1295 NO DAC, as a GHRH analogue, binds to and activates the GHRH receptor on the anterior pituitary, stimulating the cAMP/PKA signaling pathway to promote GH synthesis and release. Its modified amino acid sequence confers resistance to protease degradation, prolonging its in vivo activity. Ipamorelin, as a growth hormone secretagogue receptor (GHS-R) agonist, mimics ghrelin's action and provides complementary stimulation to the GHRH pathway. When combined, GHRH and GHS-R signaling form a "dual drive" at the pituitary level, significantly amplifying GH pulse amplitude. Notably, both compounds exhibit high selectivity, producing virtually no significant elevation of prolactin or cortisol at effective doses, rendering the secretory response "cleaner" and more closely resembling physiological GH secretion patterns induced by feeding and sleep. Furthermore, the short half-life of the NO DAC version ensures GH release occurs in pulses rather than sustained plateau-like elevations, helping maintain IGF-1 levels within an optimal range and reducing potential insulin resistance risk.
Key identity and handling information for the selected research material.
Confirm the precise CJC sequence, absence of DAC, Ipamorelin identity, and component-level assay results.
Store unopened material in its original sealed packaging, protected from light, moisture, and repeated temperature changes. Follow the product label and batch document for the exact storage temperature. After opening or preparation, use only a validated laboratory storage protocol.
Report a quality concern within 14 days of delivery with the order, batch details and available photos.
When a quality claim is approved, choose a full refund or replacement shipment.
Sales support remains available for product, documentation and wholesale inquiry follow-up.
